Edge Total Intelligence publishes restated Q2 2026 financial statements and MD&A
Bitget2026/10/10 01:00Edge Total Intelligence published amended and restated unaudited interim financial statements, replacing filings made Aug. 31, 2026. Restatement lifted loss before income taxes by USD 4.76 million to USD 6.49 million for the three months ended June 30, 2026. Net loss and comprehensive loss was restated to USD 6.38 million; basic and diluted loss per share increased to USD 0.10. Total assets fell to USD 8.99 million; total liabilities rose to USD 15.93 million as of June 30, 2026. Working capital shifted to a USD 1.11 million deficiency; cash of USD 5.84 million was unchanged. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edge Total Intelligence Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610092059NEWSFILECNPR____20261009_318489_1) on October 10, 2026, and is solely responsible for the information contained therein.
- Edge Total Intelligence published amended and restated unaudited interim financial statements, replacing filings made Aug. 31, 2026.
- Restatement lifted loss before income taxes by USD 4.76 million to USD 6.49 million for the three months ended June 30, 2026.
- Net loss and comprehensive loss was restated to USD 6.38 million; basic and diluted loss per share increased to USD 0.10.
- Total assets fell to USD 8.99 million; total liabilities rose to USD 15.93 million as of June 30, 2026.
- Working capital shifted to a USD 1.11 million deficiency; cash of USD 5.84 million was unchanged.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
No scientific evidence but viral on social media: “Bodybuilding miracle drug” peptide products deregulation file sent to the White House for review, Hims&Hers (HIMS.US) surged 6% in one day.
The temporary admission policy for peptides has been submitted to the White House for review, and compounding pharmacies are expected to receive approval to produce BPC-157 and other substances; HIMS closed up 6% on Thursday.
AiCoin丨10.16 Snapshot: PPI Exceeds Expectations, Russia Bans P2P, US Stock ETF Net Outflow
Yen barely gains on a BoJ push for hikes and a Tokyo stock rout
Crypto prices
More
